Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.
The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College’s Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
“Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy.” said Professor Girgenrath, the study’s corresponding author. “While most MD treatments are single-target therapies, we’re delving into combinations of different therapies to target multiple pathways.”
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The Latest Bing News on:
Novel Therapy to Treat Muscular Dystrophy
- Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamoroloneon October 5, 2020 at 10:33 pm
BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, October 6, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces the discontinuation of its Phase 3 SIDEROS study with ...
- Muscular Dystrophy Association Awards Five Grants Totaling Over $1.6 Million for Amyotrophic Lateral Sclerosis (ALS) Researchon September 30, 2020 at 6:00 am
PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced today the awarding of five new MDA grants totaling over $1.6 million toward research focused on amyotrophic lateral sclerosis (ALS), ...
- Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophyon September 21, 2020 at 10:09 pm
VBP15, a novel anti‐inflammatory and membrane ... drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. Link  Press release ...
- Scientists uncover a novel approach to treating Duchenne muscular dystrophyon September 15, 2020 at 10:03 am
The study, published in EMBO Reports, reveals a promising new therapeutic approach for Duchenne muscular dystrophy (DMD ... discovered the promise of this treatment almost 20 years ago and ...
- Scientists uncover a novel approach to treating Duchenne muscular dystrophyon September 14, 2020 at 5:00 pm
"We discovered the promise of this treatment almost 20 years ... "Scientists uncover a novel approach to treating Duchenne muscular dystrophy." ScienceDaily. ScienceDaily, 15 September 2020.
- Treatment with RNA-Targeting Gene Therapy Reverses Molecular and Functional Features of Myotonic Dystrophy Type 1 in Miceon September 14, 2020 at 8:11 am
Importantly, there were no significant adverse responses to the treatment ... These studies were funded in part by the Muscular Dystrophy Association (MDA). "We are delighted to support ...
The Latest Google Headlines on:
Novel Therapy to Treat Muscular Dystrophy
The Latest Bing News on:
- Teen Mom Leah Messer devastated as daughter Ali, 10, falls and hurts her foot in battle with muscular dystrophyon October 13, 2020 at 3:45 pm
LEAH Messer is left in distress while waiting to hear what’s happening with daughter Ali, 10, after she hurt her foot amid muscular dystrophy battle in Tuesday’s new Teen Mom. In a promo clip from ...
- Highland woman admits faking muscular dystrophy and breast cancer diagnoses in scamon October 13, 2020 at 10:15 am
Sarah A. Delashmit has lied repeatedly about having breast cancer, being pregnant and having muscular dystrophy, public records show.
- Muscular Dystrophy Association Announces Stars To Join The Mda Kevin Hart Kids Telethon Lineupon October 13, 2020 at 8:11 am
The Muscular Dystrophy Association today announced that Garcelle Beauvais, Aloe Blacc, Bryan Cranston, Adam Devine, Fat Joe, Liz Gillies, Aldis Hodge, Edwin Hodge, DJ Khaled, Dani ...
- FDA approves new drug to treat common form of muscular dystrophy based on research from U of A scientiston October 9, 2020 at 5:15 am
A University of Alberta researcher's past work has led to a new drug being approved for use in the United States to treat patients suffering from Duchenne muscular dystrophy (DMD).
- Neurologist receives $2.8 million grant to develop gene therapy for muscular dystrophyon October 8, 2020 at 5:00 pm
Melissa Spencer, professor of neurology and neuromuscular program director, has received a five-year, grant from the National Institutes of Health.
- New Documentary Follows Family After Sons' Muscular Dystrophy Diagnosison October 8, 2020 at 2:34 pm
What happened: A rare form of muscular dystrophy is chronicled in a new documentary where director and father Nick Taussig navigates the family’s life after his two sons are diagnosed with the ...
- Amber Specialty Pharmacy Selected by PTC Therapeutics, Inc. to Dispense EMFLAZA® for Duchenne Muscular Dystrophy Patientson October 8, 2020 at 1:50 pm
Amber Specialty Pharmacy announces that it will begin dispensing EMFLAZA® (deflazacort) to patients throughout the United States. EMFLAZA is manufactured by PTC Therapeutics, Inc., headquartered in ...
- Kevin Hart’s Muscular Dystrophy Association Telethon Relaunch Adds To Lineup; Will Stream On LOL Network – Updateon October 8, 2020 at 7:37 am
The MDA Kevin Hart Kids Telethon will benefit the Muscular Dystrophy Association and Help From the Hart. PREVIOUSLY, September 9: The Muscular Dystrophy Association will relaunch its signature ...
- Bryan Cranston, Daniel Levy, Gabrielle Union, more join Kevin Hart’s muscular dystrophy telethonon October 8, 2020 at 7:01 am
Kevin Hart’s star-studded muscular dystrophy telethon just got a lot brighter. Celebrity guests that will join Jerry Lewis' revamped fundraiser include Bryan Cranston, Adam Devine, Fat Joe, Aldis ...
- Pfizer's Gene Therapy Candidate For Duchenne Muscular Dystrophy Receives Fast Trackon October 1, 2020 at 4:16 am
(PFE) said the company's investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the FDA. The designation ...